This is a seismic shift in tone. Chris has spent many many years telling us you can’t prove a platform on one drug. Indeed, it was her modus post Alastair. I.e. this is where he got it wrong. She is now telling shareholders she believes 6000 data has proven the platform…
That can only be because she has seen sufficient data from AVA6103 to prove the platform.
Dual listing on Nasdaq won’t happen anytime soon and it’s not necessary anyhow given global pharma interest. Nomad = Strand Hanson, Sole Broker = Zeus. Peel Hunt / Panmure exited stage left - no more fee paying dead weights left
Apologies, I should have been clearer. Given Richard Hughes role as NED, it is not feasible to have Zeus as Nomad for Avacta, hence the likely appointment of a new Nomad to replace Peel Hunt